Loading…
Certara, Inc. is projected to rise to $7.01 by 2027, a +4% move from its current price of $6.77. CERT is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean strong buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/11/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 12 | $6.52 | $6.77 | $7.03 | -0.02% |
| Jul 13 | $6.42 | $6.77 | $7.14 | -0.04% |
| Jul 14 | $6.34 | $6.77 | $7.22 | -0.06% |
| Jul 15 | $6.28 | $6.76 | $7.29 | -0.08% |
| Jul 16 | $6.22 | $6.76 | $7.35 | -0.10% |
| Jul 17 | $6.17 | $6.76 | $7.41 | -0.12% |
| Jul 18 | $6.12 | $6.76 | $7.46 | -0.14% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $6.12 | $6.76 | $7.46 | -0.14% |
| Week 2 | $5.87 | $6.75 | $7.77 | -0.28% |
| Week 3 | $5.68 | $6.74 | $8.00 | -0.42% |
| Week 4 | $5.52 | $6.73 | $8.21 | -0.57% |
| Week 5 | $5.39 | $6.72 | $8.39 | -0.71% |
| Week 6 | $5.27 | $6.71 | $8.55 | -0.85% |
| Week 7 | $5.16 | $6.70 | $8.71 | -0.99% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Certara, Inc., together with its subsidiaries, provides technology-driven services and software products for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the Americas, Europe, the Middle East, Africa, and Asia Pacific. It offers model-informed drug development solutions; biosimulation solutions to predict pharmacokinetics and pharmacodynamics; Simcyp simulator, a mechanistic biosimulation platform for physiologically based pharmacokinetic simulation; Simcyp Discovery for scientists working on pre-investigational new drug and translational stages; Simcyp Biopharmaceutics for formulation scientists; and Simcyp Secondary Intelligence that integrates toxicology with quantitative analysis of large networks of molecular and functional biological changes. It also provides Phoenix WinNonlin, a platform for non-compartmental analysis; Phoenix cloud that offers a secured and validated Certara Amazon Web Services workspace; Phoenix NLME, a population modeling and simulation software; and Pirana Modeling Workbench, which provides modelers with a structure to facilitate the iterative processes.
In addition, it offers Chemaxon JChem engines, a chemical search engine; Chemaxon Compound Registration that supports a streamlined lead optimization process workflow; Chemaxon Design Hub, a design and tracking platform; Certara D360 software, a scientific informatics system; and Chemaxon Marvin, a chemical drawing tool. Further, the company provides pinnacle 21, a cloud-based platform for clinical data automation, standardization, and validation; Pinnacle 21 Data Exchange to define data standards and specifications; Metadata Repository that enables study design using controlled and standardized data; CoAuthor software, which creates and writes regulatory submissions and medical publications; and GlobalSubmit, a submissions management software. Certara Inc.
was founded in 2008 and is headquartered in Radnor, Pennsylvania.
Certara, Inc. (CERT) is a healthcare company that provides biosimulation technology and services. It operates in the Healthcare category and offers a broad portfolio of model-informed drug development and regulatory submission tools. The asset is currently priced at $6.97 with a market cap of $1.08B and is ranked 2440 by market capitalization.
A major floor 35.3% below — a decisive break under it would weaken the trend.
The nearest floor, 23.5% below — buyers have tended to step in here.
The nearest ceiling, 5.9% above — a clean break opens room to run.
A major ceiling 23.5% above — clearing it would confirm fresh momentum.
Key CERT support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of CERT market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $6.88 | Sell | $6.77 | Sell |
| MA 10 | $6.69 | Buy | $6.60 | Buy |
| MA 20 | $6.09 | Buy | $6.27 | Buy |
| MA 50 | $5.71 | Buy | $6.01 | Buy |
| MA 100 | $6.01 | Buy | $6.40 | Buy |
| MA 200 | $7.97 | Sell | $7.55 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 61.66 | Neutral |
| Stoch RSI (14) | 54.84 | Neutral |
| CCI (20) | 73.12 | Neutral |
| Williams %R (14) | -21.86 | Info |
| MACD (12,26,9) | 0.08 | Buy |
| ROC (12) | 25.37 | Buy |
| Bollinger %B (20,2) | 0.75 | Neutral |
| Stochastic %K (14) | 78.14 | Neutral |
| TRIX (15) | 0.74 | Buy |
| Awesome (5,34) | 1.05 | Buy |
| Ultimate (7,14,28) | 61.32 | Neutral |
| Momentum (10) | 1.28 | Buy |
| Aroon Osc (25) | 68.00 | Buy |
| Hull MA (9) | 6.81 | Sell |
| ADX (14) | 22.43 | Buy |
| ATR (14) | 0.21 | Info |
The 30-day technical picture shows neutral sentiment with an RSI14 of 70. The SMA50 is $5.64 and the SMA200 is $8.08, putting the price between shorter- and longer-term trend lines. The stock has a defined support at $4.67 and resistance at $6.97, with a 30-day range from $5.45 to $8.91.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $4.48 | $6.77 | $8.41 | 0% | Neutral | |
| $5.39 | $7.01 | $9.75 | +4% | Neutral | |
| $6.01 | $8.14 | $11.88 | +20% | Bullish | |
| $6.82 | $9.54 | $14.47 | +41% | Bullish | |
| $8.16 | $11.76 | $18.39 | +74% | Bullish | |
| $8.09 | $11.99 | $19.26 | +77% | Bullish | |
| $7.90 | $12.02 | $19.77 | +77% | Bullish | |
| $8.35 | $13.01 | $21.88 | +92% | Bullish | |
| $7.93 | $12.64 | $21.68 | +87% | Bullish | |
| $9.01 | $14.70 | $25.67 | +117% | Bullish | |
| $11.24 | $20.34 | $38.35 | +200% | Bullish | |
| $19.85 | $43.43 | $91.35 | +541% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $4.48 | $6.77 | $8.35 | +0.00% |
| August 2026 | $5.70 | $6.79 | $8.37 | +0.32% |
| September 2026 | $5.52 | $6.65 | $8.31 | -2.15% |
| October 2026 | $5.64 | $6.84 | $8.67 | +2.99% |
| November 2026 | $5.61 | $6.85 | $8.77 | +0.14% |
| December 2026 | $5.29 | $6.51 | $8.41 | -5.00% |
Click any year to see its month-by-month CERT forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Expect CERT to range from $4.48 to $8.41 through 2026. The $6.77 average target implies a 0% move from current prices. A consolidation phase looks the most probable path here.
The CERT price prediction for 2027 points to an average of $7.01 (low $5.39, high $9.75) — a potential gain of +4% on today's $6.77. Price action looks broadly range-bound.
In 2028, CERT is projected to trade between $6.01 and $11.88, averaging $8.14 — a potential gain of +20% from today's $6.77. That is up +16% on the projected 2027 average. Buyers look set to stay in control over this stretch.
Certara, Inc.'s 2029 outlook centres on $9.54, within a $6.82 to $14.47 range. That is up +17% on the projected 2028 average. That marks a +41% change versus current levels. Momentum favours further upside here.
By 2030, CERT could reach as high as $18.39, with a base case around $11.76 and support toward $8.16 — roughly +74% from $6.77. Buyers look set to stay in control over this stretch.
Expect CERT to range from $8.09 to $19.26 through 2031. The $11.99 average target implies a +77% move from current prices. That is up +2% on the projected 2030 average. Momentum favours further upside here.
The CERT price prediction for 2032 points to an average of $12.02 (low $7.90, high $19.77) — a potential gain of +77% on today's $6.77. Buyers look set to stay in control over this stretch.
In 2033, CERT is projected to trade between $8.35 and $21.88, averaging $13.01 — a potential gain of +92% from today's $6.77. That is up +8% on the projected 2032 average. Momentum favours further upside here.
Certara, Inc.'s 2034 outlook centres on $12.64, within a $7.93 to $21.68 range. That is -3% versus the projected 2033 average. That marks a +87% change versus current levels. Buyers look set to stay in control over this stretch.
By 2035, CERT could reach as high as $25.67, with a base case around $14.70 and support toward $9.01 — roughly +117% from $6.77. Momentum favours further upside here.
Expect CERT to range from $11.24 to $38.35 through 2040. The $20.34 average target implies a +200% move from current prices. That is up +38% on the projected 2035 average. Buyers look set to stay in control over this stretch.
The CERT price prediction for 2050 points to an average of $43.43 (low $19.85, high $91.35) — a potential gain of +541% on today's $6.77. Momentum favours further upside here.
Investing $1,000 in CERT today (≈ 147.710487 CERT) could be worth
$6,414.43
+$5,414.43 (+541%) by 2050 · US Dollar
Based on the average projected CERT price of $43.43 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in CERTwould be worth at today's price.
$1,000 invested in CERT on Jul 10, 2025 (≈ 86.956522 CERT) would be worth
$588.7
-$411.3 (-41.1%) today · 0.59× · US Dollar
Based on a CERT entry price of $11.5 vs. today's $6.77.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $6.97 | $971.31 | -2.9% |
| 1 month ago | $5.18 | $1,306.95 | +30.7% |
| 3 months ago | $5.55 | $1,219.82 | +22.0% |
| 6 months ago | $9.39 | $720.98 | -27.9% |
| 1 year ago | $11.5 | $588.7 | -41.1% |
| All time (5.0y) ago | $27.52 | $246 | -75.4% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our CERT forecast.
Our base-case forecast reaches $14.00 around 2035.
Implied market cap at $14.00: $2.18B
The multi-year forecast points to a bullish path from 2027 onward, with the 2030 average price at $13.15 and a return on investment of 88.7%. The 2040 forecast shows an average price of $24.12 with a 246% ROI, and the 2050 forecast shows an average price of $52.71 with a 656.2% ROI. These figures reflect rising expectations across the horizon, though the notes indicate these are estimates, not guarantees.
The long-run outlook remains bullish but subject to market and company-specific risks.
Tap a question to reveal the answer.
Avg $13.15, max $20.55, ROI 88.7%, sentiment BULLISH.
The forecast shows rising averages from 2026 to 2050 with bullish sentiment from 2028 onward; 2030 avg $13.15, 2040 avg $24.12, 2050 avg $52.71; ROI up to 656.2%. These are estimates and not guarantees.
The max forecast by 2050 is $110.61, indicating potential above $100 in the highest scenario.
Current price $6.97 and market cap $1.08B; rank 2440.
Low $5.45, high $8.91.
Certara, Inc. Community Discussion
0Share your Certara, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.